No Result
View All Result
Success American Investors
  • News
  • Economy
  • Editor’s Pick
  • Investing
  • Stock
  • News
  • Economy
  • Editor’s Pick
  • Investing
  • Stock
No Result
View All Result
Success American Investors
No Result
View All Result
Home Investing

Royal Mail ‘considering £430m swoop for Czech rival’

by
December 13, 2023
in Investing
0
Royal Mail ‘considering £430m swoop for Czech rival’
0
SHARES
3
VIEWS
Share on FacebookShare on Twitter

The owner of Royal Mail is reportedly considering a bid for Czech parcel giant Packeta before the latest round of bids is revealed on Friday.

International Distributions Services is said to be considering going in for the company which operations in central and eastern Europe, according to a report in The Times.

This comes after Royal Mail’s owner IDS has been blighted by widening losses, heavy strike action and reputational damage.

service obligation after trebling losses to £319m in the first half of the year, as reported last month.

According to the Times, Packeta operates in  Slovakia, Poland, Hungary, Romania and Germany in addition to the Czech Republic, and was put up for sale in May.

The potential swoop comes as Royal Mail’s debts swell to around £1.5bn, meaning further expansion could prove controversial.

Last month, IDS said it is working to improve quality after profits plunged amid a torrid year of strikes and customer let-downs.

IDS chief executive Martin Seidenberg said his number one goal is to improve the quality of the group’s services.

“From experience,” he said, “I know that quality is key for customer satisfaction and sustainable growth, so we are pulling out all the stops to deliver Christmas for our customers.”

A spokesman for International Distributions Services said: “We never comment on rumour or speculation.”

Read more:
Royal Mail ‘considering £430m swoop for Czech rival’

Previous Post

London’s Oldest New Marathon Begins: Original Marathon Launches

Next Post

Does Congress Really Believe it Can Thwart the Iron Law of Prohibition by Labeling Xylazine a Controlled Substance?

Next Post
Does Congress Really Believe it Can Thwart the Iron Law of Prohibition by Labeling Xylazine a Controlled Substance?

Does Congress Really Believe it Can Thwart the Iron Law of Prohibition by Labeling Xylazine a Controlled Substance?

Get the daily email that makes reading the news actually enjoyable. Stay informed and entertained, for free.
Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!
  • Trending
  • Comments
  • Latest
Vertica: The new Israeli start-up challenger to Viagra proving ‘life-changing’ for men with ED

Vertica: The new Israeli start-up challenger to Viagra proving ‘life-changing’ for men with ED

February 14, 2024
Brighton Palace Pier put up for sale as rising costs bite leisure sector

Brighton Palace Pier put up for sale as rising costs bite leisure sector

January 3, 2026

New working paper: “Shifting Perspectives: An Updated Survey of Environmental and Natural Resource Economists”

May 5, 2025

Last Day to Give in 2023!

December 31, 2023
The System That Rewards Excess—the Incentives Behind Overdiagnosis, Overtreatment, and Polypharmacy

The System That Rewards Excess—the Incentives Behind Overdiagnosis, Overtreatment, and Polypharmacy

0

0

0

0
The System That Rewards Excess—the Incentives Behind Overdiagnosis, Overtreatment, and Polypharmacy

The System That Rewards Excess—the Incentives Behind Overdiagnosis, Overtreatment, and Polypharmacy

January 12, 2026
When Politics Replaces Policy: The Case for Reviving Limited Government

When Politics Replaces Policy: The Case for Reviving Limited Government

January 12, 2026
Bombing Iran Risks Repeating Past Mistakes

Bombing Iran Risks Repeating Past Mistakes

January 12, 2026
National Pharmacist Day: The Most Underused Clinicians in Health Care

National Pharmacist Day: The Most Underused Clinicians in Health Care

January 12, 2026

Recent News

The System That Rewards Excess—the Incentives Behind Overdiagnosis, Overtreatment, and Polypharmacy

The System That Rewards Excess—the Incentives Behind Overdiagnosis, Overtreatment, and Polypharmacy

January 12, 2026
When Politics Replaces Policy: The Case for Reviving Limited Government

When Politics Replaces Policy: The Case for Reviving Limited Government

January 12, 2026
Bombing Iran Risks Repeating Past Mistakes

Bombing Iran Risks Repeating Past Mistakes

January 12, 2026
National Pharmacist Day: The Most Underused Clinicians in Health Care

National Pharmacist Day: The Most Underused Clinicians in Health Care

January 12, 2026

Disclaimer: SuccessAmericanInvestors.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

  • About us
  • Contact us
  • Privacy Policy
  • Terms & Conditions

Copyright © 2026 SuccessAmericanInvestors. All Rights Reserved.

No Result
View All Result
  • News
  • Economy
  • Editor’s Pick
  • Investing
  • Stock

Copyright © 2026 SuccessAmericanInvestors. All Rights Reserved.